Comparative evaluation of efficacy and safety of terbinafine and itraconazole in the management of tinea corporis et cruris

---

Original Article

Author Details : Bela Shah, Shikha Shah, Neha Jangid, Dhiraj Dhoot*, Gaurav Deshmukh

Volume : 6, Issue : 3, Year : 2020

Article Page : 231-236

https://doi.org/10.18231/j.ijced.2020.047

Suggest article by email

Get Permission

---

Abstract

Introduction: The management of dermatophytosis is challenging in India and there are reports of using systemic antifungals at higher doses. But there are multiple reports of increased treatment failures with terbinafine at standard dosage as well, hence we conducted this study to compare efficacy and safety of high dose of terbinafine with itraconazole at standard dose. Topical ciclopirox olamine was used in both arms.
Materials and Methods: This was randomized, open label, comparative study where 80 patients with tinea corporis et cruris infection were included. Patients were either prescribed terbinafine 250mg twice a day  or itraconazole 100mg twice a day for 4 weeks. Efficacy was assessed based on complete, clinical and mycological cure rate. Safety was assessed by evaluating adverse events and monitoring liver function of patients.
Results: Total 76 patients completed the study with 38 in each group. 81.5% patients achieved complete cure in terbinafine group compared to 76.31% patients in itraconazole group. At the end of six weeks, there was a statistically significant improvement (p value<0> Conclusion: This study shows that the high dose of terbinafine in combination with topical ciclopirox is effective and safe in management of tinea corporis et cruris.

Keywords: Terbinafine, Itraconazole corporis et cruris.

How to cite : Shah B, Shah S, Jangid N , Dhoot D, Deshmukh G, Comparative evaluation of efficacy and safety of terbinafine and itraconazole in the management of tinea corporis et cruris. IP Indian J Clin Exp Dermatol 2020;6(3):231-236

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.